Institutions reiterated a "Buy" rating for BEIGENE (06160), being bullish on its strong oncology drug research and development pipeline.

Recently, BEIGENE (06160) held an investor conference call to introduce important data presentations at the USA Hematology Association (ASH) and the San Antonio Breast Cancer Symposium (SABCS). Subsequently, TD Cowen Inc 7.75% Senior Notes Due 15/06/33 Usd25 reaffirmed BEIGENE's "Buy" rating and maintained a Target Price of $260.00, which aligns with the consensus of many Analysts who believe that this Stocks has potential for upward movement.

Zhitong Finance13:36

US stocks movement | BEIGENE continues to rise 0.84% in pre-market trading with several Institutions giving it a Buy rating.

Gelonghui, December 18 | Yesterday, BEIGENE (BGNE.US) closed up 1.55%, and in Pre-Market Trading today, it continued to rise by 0.84%, reaching $180.56. Analyst Kelly Shi from Jefferies Group maintains a Buy rating for BEIGENE and keeps the Target Price at $286. TD Cowen Inc 7.75% Senior Notes Due 15/06/33 Usd25 analyst Yaron Werber also maintains a Buy rating for BEIGENE with a Target Price of $260. (Gelonghui)

Gelonghui FinanceDec 18 17:16

TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260

Futu NewsDec 17 20:33 · Ratings

BeiGene (BGNE) Gets a Buy From TD Cowen

TipRanksDec 17 20:15 · Ratings

BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials

TipRanksDec 17 13:25

Express News | According to the Hong Kong Stock Exchange: On December 11, JPMorgan's short position in BEIGENE decreased from 2.42% to 1.66%.

BreakingsDec 16 17:34